Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth

31 1 月, 2026

One Min Read

8 Views

原文: https://finance.yahoo.com/news/analyst-views-diverge-alnylam-pharmaceuticals-143556394.html

Last Update: 31 1 月, 2026

Written By

Other Articles

Previous

CVS Health Corporation (CVS) Positioned for Long-Term Growth Amid Policy Shifts

Next

Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW)

Related Posts

Powerball jackpot soars to $1.3 billion. Here’s what the winner will take home after taxes.

1 Min Read

What is force-placed car insurance, and when do lenders require it?

1 Min Read

Do you need collateral for a personal loan? See when it might help.

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept